Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$25.60
-0.29-1.12%
À la fermeture: -
$25.70
0.10.39%
Après les heures de négociation: Oct 24, 7:39 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Intellia Therapeutics Inc a un objectif de cours consensus de $42.71, basé sur les évaluations des 28 analystes. Le plus élevé est de $116 attribué par EF Hutton le février 24, 2023, et le plus bas est de $10 attribué par Wedbush le mai 19, 2025. Les 3 dernières évaluations d'analystes ont été publiées par JMP Securities, HC Wainwright & Co. et Guggenheim le octobre 6, 2025, septembre 19, 2025 et août 13, 2025. Avec un objectif de cours moyen de $25.67 entre JMP Securities, HC Wainwright & Co. et Guggenheim, il y a une variation implicite de -0.13% downside pour Intellia Therapeutics Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
JMP Securities
HC Wainwright & Co.
Guggenheim
Chardan Capital
RBC Capital
1calculé à partir des notes des analystes
Notes d'analystes pour Intellia Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/06/2025 | 28.4% | JMP Securities | → $33 | Upgrade | Market Perform → Market Outperform | |||
09/19/2025 | — | JMP Securities | — | Reiterates | Market Perform → Market Perform | |||
09/19/2025 | 16.73% | HC Wainwright & Co. | $25 → $30 | Maintains | Buy | |||
08/13/2025 | -45.53% | Guggenheim | $45 → $14 | Maintains | Buy | |||
08/11/2025 | 133.46% | Chardan Capital | $68 → $60 | Maintains | Buy | |||
08/08/2025 | -18.29% | RBC Capital | $25 → $21 | Maintains | Outperform | |||
08/08/2025 | 75.1% | Wells Fargo | $50 → $45 | Maintains | Overweight | |||
08/08/2025 | -2.72% | HC Wainwright & Co. | $30 → $25 | Maintains | Buy | |||
06/16/2025 | 16.73% | HC Wainwright & Co. | $30 → $30 | Reiterates | Buy → Buy | |||
06/03/2025 | 110.12% | Canaccord Genuity | $74 → $54 | Maintains | Buy | |||
05/29/2025 | 16.73% | HC Wainwright & Co. | $30 → $30 | Reiterates | Buy → Buy | |||
05/20/2025 | 16.73% | HC Wainwright & Co. | $30 → $30 | Reiterates | Buy → Buy | |||
05/19/2025 | -61.09% | Wedbush | $10 → $10 | Reiterates | Neutral → Neutral | |||
05/12/2025 | 75.1% | Guggenheim | $55 → $45 | Maintains | Buy | |||
05/09/2025 | -61.09% | Citigroup | $14 → $10 | Maintains | Neutral | |||
05/09/2025 | 164.59% | Chardan Capital | $68 → $68 | Maintains | Buy | |||
04/21/2025 | -18.29% | Wolfe Research | → $21 | Upgrade | Peer Perform → Outperform | |||
03/05/2025 | 16.73% | HC Wainwright & Co. | → $30 | Initiates | → Buy | |||
03/04/2025 | 94.55% | Truist Securities | $90 → $50 | Maintains | Buy | |||
02/28/2025 | 1.17% | Barclays | $55 → $26 | Maintains | Overweight | |||
02/28/2025 | -45.53% | Citigroup | $12 → $14 | Maintains | Neutral | |||
02/28/2025 | 94.55% | Wells Fargo | $60 → $50 | Maintains | Overweight | |||
02/28/2025 | 164.59% | Chardan Capital | $91 → $68 | Maintains | Buy | |||
02/28/2025 | -49.42% | JP Morgan | $45 → $13 | Downgrade | Overweight → Neutral | |||
01/27/2025 | -57.2% | Morgan Stanley | $56 → $11 | Downgrade | Overweight → Equal-Weight | |||
01/14/2025 | -53.31% | Goldman Sachs | $19 → $12 | Maintains | Neutral | |||
01/13/2025 | 55.64% | Oppenheimer | $60 → $40 | Maintains | Outperform | |||
01/10/2025 | 133.46% | Wells Fargo | $70 → $60 | Maintains | Overweight | |||
01/10/2025 | 94.55% | BMO Capital | $70 → $50 | Maintains | Outperform | |||
11/19/2024 | 250.19% | Canaccord Genuity | $90 → $90 | Maintains | Buy | |||
11/18/2024 | 172.37% | Wells Fargo | $80 → $70 | Maintains | Overweight | |||
11/18/2024 | -45.53% | Wedbush | $14 → $14 | Reiterates | Neutral → Neutral | |||
11/18/2024 | 254.09% | Chardan Capital | $88 → $91 | Maintains | Buy | |||
11/11/2024 | 133.46% | Oppenheimer | $70 → $60 | Maintains | Outperform | |||
11/08/2024 | 114.01% | Barclays | $76 → $55 | Maintains | Overweight | |||
10/25/2024 | -26.07% | Citigroup | $25 → $19 | Maintains | Neutral | |||
10/25/2024 | -22.18% | Goldman Sachs | $31 → $20 | Maintains | Neutral | |||
10/25/2024 | -29.96% | Baird | $24 → $18 | Maintains | Neutral | |||
10/24/2024 | 242.41% | Chardan Capital | $94 → $88 | Maintains | Buy | |||
09/19/2024 | 110.12% | RBC Capital | $54 → $54 | Reiterates | Outperform → Outperform | |||
09/17/2024 | 59.53% | Jones Trading | → $41 | Initiates | → Buy | |||
09/11/2024 | 149.03% | Stifel | $80 → $64 | Maintains | Buy | |||
08/12/2024 | 114.01% | JP Morgan | $61 → $55 | Maintains | Overweight | |||
08/09/2024 | 110.12% | RBC Capital | $60 → $54 | Maintains | Outperform | |||
06/27/2024 | 184.05% | Canaccord Genuity | $73 → $73 | Maintains | Buy | |||
06/24/2024 | 152.92% | Cantor Fitzgerald | $65 → $65 | Reiterates | Overweight → Overweight | |||
06/24/2024 | 366.93% | Truist Securities | $120 → $120 | Maintains | Buy | |||
06/18/2024 | 152.92% | Cantor Fitzgerald | $65 → $65 | Reiterates | Overweight → Overweight | |||
06/04/2024 | 152.92% | Cantor Fitzgerald | $65 → $65 | Reiterates | Overweight → Overweight | |||
05/10/2024 | 12.84% | Citigroup | $31 → $29 | Maintains | Neutral | |||
05/10/2024 | 172.37% | BMO Capital | $62 → $70 | Maintains | Outperform | |||
04/23/2024 | 12.84% | Wedbush | $29 → $29 | Reiterates | Neutral → Neutral | |||
02/23/2024 | 24.51% | Goldman Sachs | → $32 | Downgrade | Buy → Neutral | |||
02/23/2024 | 184.05% | Canaccord Genuity | $72 → $73 | Maintains | Buy | |||
02/15/2024 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
11/13/2023 | 172.37% | Oppenheimer | $80 → $70 | Maintains | Outperform | |||
11/13/2023 | 230.74% | Morgan Stanley | $90 → $85 | Maintains | Overweight | |||
11/10/2023 | 141.25% | BMO Capital | $64 → $62 | Maintains | Outperform | |||
11/10/2023 | 172.37% | RBC Capital | $80 → $70 | Maintains | Outperform | |||
11/10/2023 | 429.18% | Goldman Sachs | $157 → $136 | Maintains | Buy | |||
11/10/2023 | 121.79% | Raymond James | $78 → $57 | Maintains | Outperform | |||
11/09/2023 | 12.84% | Wedbush | $45 → $29 | Maintains | Neutral | |||
09/13/2023 | 152.92% | Cantor Fitzgerald | → $65 | Reiterates | Overweight → Overweight | |||
08/29/2023 | 152.92% | Cantor Fitzgerald | → $65 | Reiterates | Overweight → Overweight | |||
08/09/2023 | 152.92% | Cantor Fitzgerald | → $65 | Reiterates | Overweight → Overweight | |||
08/07/2023 | 250.19% | Barclays | $86 → $90 | Maintains | Overweight | |||
08/07/2023 | 152.92% | Canaccord Genuity | $66 → $65 | Maintains | Buy | |||
08/07/2023 | 316.34% | Chardan Capital | → $107 | Reiterates | Buy → Buy | |||
08/04/2023 | 55.64% | Citigroup | $44 → $40 | Maintains | Neutral | |||
08/04/2023 | 250.19% | Barclays | $148 → $90 | Maintains | Overweight | |||
06/13/2023 | 254.09% | B of A Securities | $89 → $91 | Maintains | Buy | |||
06/13/2023 | 316.34% | Chardan Capital | $111 → $107 | Maintains | Buy | |||
06/13/2023 | 195.72% | Credit Suisse | → $76 | Reiterates | Outperform → Outperform | |||
05/08/2023 | 71.21% | Citigroup | $39 → $44 | Maintains | Neutral | |||
05/08/2023 | 250.19% | Oppenheimer | $93 → $90 | Maintains | Outperform | |||
05/08/2023 | 234.63% | Morgan Stanley | $83 → $86 | Maintains | Overweight | |||
05/05/2023 | 149.03% | BMO Capital | $57 → $64 | Maintains | Outperform | |||
05/05/2023 | 203.5% | Raymond James | $94 → $78 | Maintains | Outperform | |||
04/13/2023 | 156.81% | Canaccord Genuity | → $66 | Initiates | → Buy | |||
03/31/2023 | 207.39% | JP Morgan | $82 → $79 | Maintains | Overweight | |||
03/21/2023 | 110.12% | Bernstein | → $54 | Initiates | → Outperform | |||
03/14/2023 | 121.79% | BMO Capital | $54 → $57 | Upgrade | Market Perform → Outperform | |||
02/27/2023 | 331.91% | Chardan Capital | $129 → $111 | Maintains | Buy | |||
02/24/2023 | 195.72% | Credit Suisse | $88 → $76 | Maintains | Outperform | |||
02/24/2023 | 261.87% | Oppenheimer | $115 → $93 | Maintains | Outperform | |||
02/24/2023 | 63.42% | Baird | $58 → $42 | Maintains | Neutral | |||
02/24/2023 | 351.36% | EF Hutton | $123 → $116 | Maintains | Buy | |||
02/24/2023 | 265.76% | Raymond James | $124 → $94 | Maintains | Outperform | |||
02/01/2023 | 160.7% | Cantor Fitzgerald | → $67 | Initiates | → Overweight | |||
01/24/2023 | 51.75% | Citigroup | $48 → $39 | Upgrade | Sell → Neutral | |||
01/23/2023 | 226.85% | SVB Leerink | $86 → $84 | Maintains | Outperform | |||
01/19/2023 | — | JMP Securities | — | Downgrade | Market Outperform → Market Perform | |||
01/04/2023 | 366.93% | Wells Fargo | $135 → $120 | Maintains | Overweight | |||
12/06/2022 | 242.41% | Credit Suisse | $109 → $88 | Maintains | Outperform | |||
12/02/2022 | 234.63% | SVB Leerink | $90 → $86 | Maintains | Outperform | |||
11/15/2022 | 401.95% | Chardan Capital | $121 → $129 | Maintains | Buy | |||
11/04/2022 | 378.6% | EF Hutton | $130 → $123 | Maintains | Buy | |||
11/04/2022 | 222.96% | Morgan Stanley | $84 → $83 | Maintains | Overweight | |||
11/04/2022 | 382.49% | Raymond James | $127 → $124 | Maintains | Outperform | |||
11/04/2022 | 324.12% | Credit Suisse | $101 → $109 | Maintains | Outperform |
FAQ
Quel est le cours indicatif de l'action Intellia Therapeutics (NTLA) ?
Le dernier objectif de prix pour Intellia Therapeutics (NASDAQ:NTLA) a été rapporté par JMP Securities le octobre 6, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $33.00 s'attendant à ce que NTLA se rise dans les 12 prochains mois (un possible changement de 28.40% upside). 35 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Intellia Therapeutics (NTLA) ?
La dernière note d'analyste pour Intellia Therapeutics (NASDAQ:NTLA) a été fournie par JMP Securities, et Intellia Therapeutics amélioré leur note market outperform.
Quand a eu lieu la dernière mise à niveau pour Intellia Therapeutics (NTLA) ?
La dernière amélioration pour Intellia Therapeutics Inc a eu lieu le octobre 6, 2025 lorsque JMP Securities a augmenté leur objectif de prix à $33. JMP Securities avait précédemment a market perform pour Intellia Therapeutics Inc.
Quand a eu lieu la dernière dégradation pour Intellia Therapeutics (NTLA) ?
La dernière réduction pour Intellia Therapeutics Inc a eu lieu le février 28, 2025 lorsque JP Morgan a changé leur objectif de prix de $45 à $13 pour Intellia Therapeutics Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Intellia Therapeutics (NTLA) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Intellia Therapeutics, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Intellia Therapeutics a été déposée le octobre 6, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 6, 2026.
La note d'analyste pour Intellia Therapeutics (NTLA) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Intellia Therapeutics (NTLA) était un amélioré avec un objectif de prix de $0.00 à $33.00. Le prix actuel de Intellia Therapeutics (NTLA) est de $25.70, ce qui est within la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.